1 week Ago By ABMN Staff
Gyre Therapeutics, Inc. ( NASDAQ:GYRE – Get Free Report )’s stock price shot up 6.6% during trading on Friday .
The stock traded as high as $12.60 and last traded at $12.60.
44,962 shares were traded during mid-day trading, a decline of 38% from the average session volume of 72,367 shares. The stock had previously closed at $11.82.
Gyre Therapeutics Stock Performance The business has a 50-day moving average price of $12.71 and a two-hundred day moving average price of $14.33.
Gyre Therapeutics ( NASDAQ:GYRE – Get Free Report ) last posted its earnings results on Tuesday, August 13th. The company reported $0.01 EPS for the quarter.
The firm had revenue of $25.23 million for the quarter. As a group, research analysts forecast that Gyre Therapeutics, Inc.
will post -0.45 EPS for the current fiscal year. Insider Buying and Selling Institutional Trading of Gyre Therapeutics A number of hedge funds have recently added to or reduced their stakes in the business.
Rhumbline Advisers purchased a new position in Gyre Therapeutics in the 2nd quarter valued at about $123,000. Renaissance Technologies LLC bought a new stake in Gyre Therapeutics during the second quarter valued at $166,000. Bank of New York Mellon Corp bought a new position in Gyre Therapeutics in the second quarter worth about $218,000.
Finally, WINTON GROUP Ltd acquired a new position in Gyre Therapeutics during the 2nd quarter valued at approximately $220,000. 23.99% of the stock is owned by institutional investors and hedge funds.
About Gyre Therapeutics ( Get Free Report ) Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. Featured Stories Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
